Back to Journals » Clinical Ophthalmology » Volume 11

Switching to preservative-free latanoprost: impact on tolerability and patient satisfaction

Authors Muñoz Negrete FJ, Lemij HG, Erb C

Received 28 October 2016

Accepted for publication 12 January 2017

Published 21 March 2017 Volume 2017:11 Pages 557—566

DOI https://doi.org/10.2147/OPTH.S126042

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Amy Norman

Peer reviewer comments 3

Editor who approved publication: Dr Scott Fraser

Francisco José Muñoz Negrete,1 Hans G Lemij,2 Carl Erb3

1Ophthalmology Service, Hospital Ramón y Cajal, Madrid, Spain; 2Glaucoma Service, Rotterdam Eye Hospital, Rotterdam, the Netherlands; 3Augenklinik Wittenbergplatz, Berlin, Germany

Abstract: Patient satisfaction with glaucoma treatment has been poorly studied to date. Because glaucoma is a chronic condition in which the therapeutic response is dependent on adherence to treatment, patient acceptability is an important factor in achieving satisfactory outcomes. This multicenter, international (Belgium, the Netherlands, and Spain), epidemiological convenience sample survey among patients commencing treatment with preservative-free latanoprost collected data on patient satisfaction with particular regard to tolerability. A total of 1,541 patients were recruited who were predominantly elderly (74% were over 60 years of age) and female (61%). Most of the patients had previously received preserved topical glaucoma medication (69%), 6.7% had previously received preservative-free medication, whereas 24% had not previously been treated for glaucoma. The great majority of patients (>95%) were satisfied with the preservative-free latanoprost treatment. Among the patients who had previously received preserved medication, 73% of patients found preservative-free latanoprost to be better tolerated and 89% found it at least as easy to use as their prior treatment. Patient satisfaction (determined by a 0–100 mm visual analog scale) was improved by 47% on a switch from preserved treatment to preservative-free latanoprost. Intraocular pressure was similar in patients who had previously received preserved (18.3 mmHg), preservative-free (17.8 mmHg) glaucoma medication or who were naïve to treatment (20.3 mmHg). Preservative-free latanoprost provided effective reduction of intraocular pressure with better tolerability and patient satisfaction than preserved glaucoma medication. This tolerability profile can be expected to improve adherence to treatment in glaucoma patients.

Keywords: prostaglandins analogs, glaucoma therapy, preservative, patient satisfaction, tolerability, persistence, tear substitutes

Corrigendum for this paper has been published
A Letter to the Editor has been received and published for this article.


Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other articles by this author:

Switching to preservative-free latanoprost: impact on tolerability and patient satisfaction [Corrigendum]

Muñoz Negrete FJ, Lemij HG, Erb C

Clinical Ophthalmology 2017, 11:887-888

Published Date: 11 May 2017

Patient satisfaction with glaucoma therapy: reality or myth?

Lemij HG, Hoevenaars JGMM, van der Windt C, Baudouin C

Clinical Ophthalmology 2015, 9:785-793

Published Date: 4 May 2015

A 3-day regimen with azithromycin 1.5% eyedrops for the treatment of purulent bacterial conjunctivitis in children: efficacy on clinical signs and impact on the burden of illness

Bremond-Gignac D, Messaoud R, Lazreg S, Speeg-Schatz C, Renault D, Chiambaretta F

Clinical Ophthalmology 2015, 9:725-732

Published Date: 20 April 2015

A randomized crossover study comparing trehalose/hyaluronate eyedrops and standard treatment: patient satisfaction in the treatment of dry eye syndrome

Pinto-Bonilla JC, del Olmo-Jimeno A, Llovet-Osuna F, Hernández-Galilea E

Therapeutics and Clinical Risk Management 2015, 11:595-603

Published Date: 13 April 2015

European survey on the opinion and use of micronutrition in age-related macular degeneration: 10 years on from the Age-Related Eye Disease Study

Aslam T, Delcourt C, Holz F, García-Layana A, Leys A, Silva RM, Souied E

Clinical Ophthalmology 2014, 8:2045-2053

Published Date: 10 October 2014

Evaluation of the efficacy, safety, and acceptability of an eyelid warming device for the treatment of meibomian gland dysfunction

Benitez del Castillo JM, Kaercher T, Mansour K, Wylegala E, Dua H

Clinical Ophthalmology 2014, 8:2019-2027

Published Date: 6 October 2014

Latanoprost in the treatment of glaucoma

Alm A

Clinical Ophthalmology 2014, 8:1967-1985

Published Date: 26 September 2014

Use of preservative-free hyaluronic acid (Hylabak®) for a range of patients with dry eye syndrome: experience in Russia

Brzhesky VV, Maychuk YF, Petrayevsky AV, Nagorsky PG

Clinical Ophthalmology 2014, 8:1169-1177

Published Date: 18 June 2014

Topical azithromycin or ofloxacin for endophthalmitis prophylaxis after intravitreal injection

Romero-Aroca P, Sararols L, Arias L, Casaroli-Marano RP, Bassaganyas F

Clinical Ophthalmology 2012, 6:1595-1599

Published Date: 9 October 2012

Tolerability and acceptability of Blephagel: a novel eyelid hygiene aqueous gel

Doan S

Clinical Ophthalmology 2012, 6:71-77

Published Date: 11 January 2012

Do neurologists in Germany adhere to the national Parkinson's disease guideline?

Sabrina Schröder, Daniel Kuessner, Guy Arnold, et al

Neuropsychiatric Disease and Treatment 2011, 7:103-110

Published Date: 7 March 2011